Trinomab Listed in 2022 Future Healthcare VB100 —— The Top 100 China Innovative Biomedicine List 2022-06-23

On June 15, 2022, the long-anticipated 2022 Future Healthcare VB100 list was officially released in the 6th Future Healthcare VB100 Virtual Summit. Trinomab was listed in the 2022 Future Healthcare VB100 —— The Top 100 China Innovative Biomedicine list.


VB100, VCBEAT and VBR has jointly launched the first list of innovative medical field which aim at non-stock company in China-The Future Healthcare VB 100 list. It aims to select Chinese innovative companies that truly represent the future of medical care and to discover the backbone of China’s future medical industry. VB 100 list has become the most popular annual list in healthcare field among industrial circles and investors. The Top 100 innovative companies were selected based on a portfolio of indexes, including human resource, intellectual property, key partners, market performance and etc.


As a clinical stage biopharmaceutical company with global expansion perspective, Trinomab is mainly engaged in R&D and commercialization of novel fully human monoclonal antibody(mAb) drugs. It has attracted many investors including GL Ventures, CMB International Capital, China International Capital and Riverhead Capital by virtue of its comprehensive strength and great potential in core technology, R&D capacity, pipeline progress, market prospect and etc. By December, 2021, Trinomab had completed 1.3 billion of equity financing. Its self-developed anti-tetanus toxin fully native human mAbs and anti-RSV fully native human mAbs have entered clinical stage, among which, anti-tetanus toxin fully native human mAbs TNM002 injection was included in the Breakthrough Therapy Drug Program by the Center for Drug Evaluation(CDE) of the National Medical Products Administration(NMPA) in March, 2022 and is the world’s only fully native human mAb that entered clinical stage.


Being listed in VB100 means Trinomab has received wide recognition in healthcare industry. Upholding the mission of “creating clinical value”, Trinomab will continue to work hard toward the goal to develop novel therapeutics that will benefit patients across the globe.